Natural Product (NP) Details
| General Information of the NP (ID: NP6882) | |||||
|---|---|---|---|---|---|
| Name |
Arctigenin
|
||||
| Synonyms |
Arctigenin; (-)-Arctigenin; 7770-78-7; UNII-U76MR9VS6M; C21H24O6; CHEBI:79; U76MR9VS6M; (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)dihydrofuran-2(3H)-one; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R-trans)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3H)-furanone; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3- [(4-hydroxy-3-methoxyphenyl)methyl]-2-tetrahydrofuranone; (+/-)-Arctigenin; Arctigenin, (+/-)-; Arctigenen; Arctigenin, trans-((+/-)-; 2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-, (3R,4R)-; Tocris-1777; SCHEMBL381820; CHEMBL435734; MEGxp0_001799; ACon1_000416; DTXSID60998919; HMS3268E18; HMS3412H04; HMS3676H04; HY-N0035; ZINC1615344; BDBM50375656; MFCD00870597; s3897; STL565840; AKOS015897121; CCG-268327; MCULE-1275881531; MCULE-5621583813; NCGC00025291-01; NCGC00025291-02; NCGC00025291-04; 144901-91-7; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-rel-; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, trans-; AS-56162; AB0019692; (-)-Arctigenin, >=95% (LC/MS-ELSD); N2399; C10545; 770A787; SR-01000597504; Q-100825; Q4787603; SR-01000597504-1; BRD-K53523901-001-01-0; UNII-2FD8L150E7 component NQWVSMVXKMHKTF-JKSUJKDBSA-N; 4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(3-methoxy-4-oxidanyl-phenyl)methyl]oxolan-2-one; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]tetrahydrofuran-2-one; (3R-trans)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy- 3-methoxyphenyl)methyl]-4,5-dihydrofuran-2(3H)-one; 4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-(3R,4R)-2(3H)-Furanone; 4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-(3R-trans)-2(3H)-Furanone; EQC
Click to Show/Hide
|
||||
| Species Origin | Arctium lappa ... | Click to Show/Hide | |||
| Arctium lappa | |||||
| Disease | Depression [ICD-11: 6A70-6A71] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C21H24O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=C(C=C(C=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)O)OC)OC
|
||||
| InChI |
1S/C21H24O6/c1-24-18-7-5-13(11-20(18)26-3)8-15-12-27-21(23)16(15)9-14-4-6-17(22)19(10-14)25-2/h4-7,10-11,15-16,22H,8-9,12H2,1-3H3/t15-,16+/m0/s1
|
||||
| InChIKey |
NQWVSMVXKMHKTF-JKSUJKDBSA-N
|
||||
| CAS Number |
CAS 7770-78-7
|
||||
| ChEBI ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Arctigenin has a therapeutic potential in combination with chemotherapeutic agents for NSLC. | |||||
| Ultraviolet A irradiation | Systemic sclerosis | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Human mesenchymal stem cells derived from adipose tissue | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Arctigenin protects against ultraviolet-A-induced damage to stemness through inhibition of the NF-KappaB/MAPK pathway. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
ATG might alleviate the side effects and improve the therapeutic efficacy of DOX. | |||||
